Google Inc vs uniQure N.V. Ordinary Shares — how do they compare? Google Inc trades at $337.75 (market cap $4.30T), while uniQure N.V. Ordinary Shares trades at $20.78 (market cap $1.48B). The key difference: Google Inc is far larger — about 2905.4× uniQure N.V. Ordinary Shares's market cap, and Google Inc pays a 0.25% dividend while uniQure N.V. Ordinary Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Google Inc for 138 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| GOOG | QURE | |
|---|---|---|
Market Cap | $4.30T | $1.48B |
Volume | 14,394,061 | 2,488,780 |
Sector | Media | Health |
52-Week High | $399.06 | $70.59 |
52-Week Low | $251.34 | $9.03 |
Typical Hold Time | 138 Days | 0 Days |
Enterprise Value | $4.19T | $728.62M |
Dividend Yield | 0.25% | — |
Signals from Pluang's Aura AI — not financial advice
Alphabet (GOOG) trades at $343.65, down 1.52% on the day, with strong technical momentum indicated by bullish moving averages. The company demonstrates robust fundamentals with Q2 2026 EPS of $9.11 beating expectations by 218%, revenue growth accelerating to $402.84B in 2025, and net income margin expanding to 54.77%. Recent news highlights significant AI investments and legal challenges.
Alphabet presents a compelling investment case with strong earnings momentum and dominant market position, though investors face risks from aggressive capital expenditure, potential negative free cash flow, and ongoing securities litigation. The consensus price target of $435.24 suggests 27% upside potential from current levels.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Alphabet Inc. operates as a holding company. The Company, through its subsidiaries, provides web-based search, advertisements, maps, software applications, mobile operating systems, consumer content, enterprise solutions, commerce, and hardware products.
Read more on GOOG →uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →